Back to top
more

Mirati Therapeutics, Inc. (MRTX)

(Delayed Data from NSDQ)

$195.60 USD

195.60
327,177

-7.30 (-3.60%)

Updated Feb 25, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (199 out of 253)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Amgen (AMGN) Files for KRAS Inhibitor for Lung Cancer in Europe

The regulatory filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which shows that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.

Amgen (AMGN) Submits NDA for KRAS Inhibitor for Lung Cancer

The NDA filing for Amgen's (AMGN) sotorasib is based on data from a phase II study, which showed that sotorasib led to durable anticancer activity in advanced NSCLC patients with KRAS G12C mutation.

Amgen's (AMGN) KRAS Inhibitor Gets Breakthrough Tag for NSCLC

The FDA bestows a Breakthrough Therapy status on Amgen's (AMGN) KRAS inhibitor, sotorasib, for treating patients with advanced/metastatic non-small-cell lung cancer with KRAS G12C mutation.

Why Is Mirati (MRTX) Down 2.2% Since Last Earnings Report?

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of 3.92% and 1580.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Mirati Therapeutics (MRTX) Might Surprise This Earnings Season

Mirati Therapeutics (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Mirati (MRTX) Expected to Beat Earnings Estimates: Should You Buy?

Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirati (MRTX) Up 6.8% Since Last Earnings Report: Can It Continue?

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Analysts Estimate Mirati (MRTX) to Report a Decline in Earnings: What to Look Out for

Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirati (MRTX) Up 4.1% Since Last Earnings Report: Can It Continue?

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirati (MRTX) Reports Q1 Loss, Lags Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of -22.42% and -58.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Mirati (MRTX) to Report a Decline in Earnings: What to Look Out for

Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

4 Drug/Biotech Outperformers That May Lose Steam in 2020

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

Options Traders Expect Huge Moves in Mirati (MRTX) Stock

Investors need to pay close attention to Mirati (MRTX) stock based on the movements in the options market lately.

Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of -8.66% and 97.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Mirati Therapeutics (MRTX) Stock?

Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.

Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group

Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.

Mirati Inks Deal with Novartis to Evaluate Tumor Candidate

Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.

Implied Volatility Surging for Mirati Therapeutics (MRTX) Stock Options

Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.

Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity

At ASCO, Amgen (AMGN) presented encouraging initial data set for AMG 510, its novel investigational KRAS inhibitor for solid tumor.

Neena Mishra headshot

Why Cancer-Fighting Stocks & ETFs Are Soaring

The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock

Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.

Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%

Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Neena Mishra headshot

Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy

2018 Nobel Prize for medicine was awarded for immunotherapy research. Here is what investors need to know about stocks and ETF focused on this innovative area.

Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS